226 related articles for article (PubMed ID: 10854138)
1. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
[TBL] [Abstract][Full Text] [Related]
3. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
[TBL] [Abstract][Full Text] [Related]
5. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
6. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
8. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.
Jung C; Bogner JR; Goebel F
Eur J Med Res; 1998 Sep; 3(9):439-42. PubMed ID: 9737891
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
[TBL] [Abstract][Full Text] [Related]
11. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
Nannan Panday VR; Hoetelmans RM; van Heeswijk RP; Meenhorst PL; Inghels M; Mulder JW; Beijnen JH
Cancer Chemother Pharmacol; 1999; 43(6):516-9. PubMed ID: 10321513
[TBL] [Abstract][Full Text] [Related]
13. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel for treating KS.
Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
[TBL] [Abstract][Full Text] [Related]
15. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).
Bendle M; Pealing J; Papanastasopoulos P; Bower M
Cancer Chemother Pharmacol; 2014 Sep; 74(3):611-5. PubMed ID: 25055936
[TBL] [Abstract][Full Text] [Related]
16. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.
Rosenthal E; Poizot-Martin I; Saint-Marc T; Spano JP; Cacoub P;
Am J Clin Oncol; 2002 Feb; 25(1):57-9. PubMed ID: 11823698
[TBL] [Abstract][Full Text] [Related]
17. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir.
Martinelli C; Zazzi M; Ambu S; Bartolozzi D; Corsi P; Leoncini F
AIDS; 1998 Sep; 12(13):1717-9. PubMed ID: 9764794
[No Abstract] [Full Text] [Related]
18. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
[TBL] [Abstract][Full Text] [Related]
20. DaunoXome offers KS treatment alternative.
AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
